MX2022001874A - Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos. - Google Patents

Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.

Info

Publication number
MX2022001874A
MX2022001874A MX2022001874A MX2022001874A MX2022001874A MX 2022001874 A MX2022001874 A MX 2022001874A MX 2022001874 A MX2022001874 A MX 2022001874A MX 2022001874 A MX2022001874 A MX 2022001874A MX 2022001874 A MX2022001874 A MX 2022001874A
Authority
MX
Mexico
Prior art keywords
nonpeptide
receptor agonists
somatostatin type
compounds
somatostatin
Prior art date
Application number
MX2022001874A
Other languages
English (en)
Inventor
Mi Chen
Shimiao Wang
Jian Zhao
Yunfei Zhu
Joseph Pontillo
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of MX2022001874A publication Critical patent/MX2022001874A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

En el presente documento se describen compuestos que son moduladores de somatostatina, métodos para preparar dichos compuestos, composiciones farmacéuticas y medicamentos que comprenden estos compuestos, y métodos para la utilización de dichos compuestos en el tratamiento de afecciones, enfermedades, o trastornos que pueden beneficiarse de la modulación de la actividad de la somatostatina.
MX2022001874A 2019-08-14 2020-08-10 Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos. MX2022001874A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962886764P 2019-08-14 2019-08-14
PCT/US2020/045610 WO2021030262A1 (en) 2019-08-14 2020-08-10 Nonpeptide somatostatin type 5 receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2022001874A true MX2022001874A (es) 2022-03-11

Family

ID=74568328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001874A MX2022001874A (es) 2019-08-14 2020-08-10 Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.

Country Status (16)

Country Link
US (2) US11479540B2 (es)
EP (1) EP4013748A4 (es)
JP (1) JP2022544055A (es)
KR (1) KR20220047318A (es)
CN (1) CN114585614A (es)
AR (1) AR119753A1 (es)
AU (1) AU2020327950A1 (es)
BR (1) BR112022002683A2 (es)
CA (1) CA3149840A1 (es)
CL (1) CL2022000354A1 (es)
CO (1) CO2022002781A2 (es)
IL (1) IL290479A (es)
MX (1) MX2022001874A (es)
PE (1) PE20221402A1 (es)
WO (1) WO2021030262A1 (es)
ZA (1) ZA202201829B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019157458A1 (en) 2018-02-12 2019-08-15 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TW202024095A (zh) 2018-09-18 2020-07-01 美商克林提克斯醫藥股份有限公司 生長抑制素(somatostatin)調節劑及其用途
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
BR112022002683A2 (pt) 2019-08-14 2022-07-05 Crinetics Pharmaceuticals Inc Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos
US11773076B2 (en) 2021-02-17 2023-10-03 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator
IL305015A (en) * 2021-02-17 2023-10-01 Crinetics Pharmaceuticals Inc Crystal forms of a somatostatin modulator
WO2024089668A1 (en) * 2022-10-28 2024-05-02 Basecamp Bio Inc. Somatostatin receptor 2 agonists and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127343A (en) 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
CA2644929A1 (en) 2006-03-13 2008-05-02 Merck & Co., Inc. Somatostatin agonists
CN101506165B (zh) 2006-08-15 2012-07-04 霍夫曼-拉罗奇有限公司 苯基、吡啶和喹啉衍生物
EP2211619A1 (en) 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
EP2297131A2 (en) * 2008-06-25 2011-03-23 Envivo Pharmaceuticals, Inc. Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
WO2011146324A1 (en) 2010-05-18 2011-11-24 Merck Sharp & Dohme Corp. Spiro isoxazoline compounds as sstr5 antagonists
GB201008290D0 (en) 2010-05-18 2010-06-30 Syngenta Ltd Chemical compounds
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
KR20160062023A (ko) 2013-09-30 2016-06-01 오노 야꾸힝 고교 가부시키가이샤 소마토스타틴 수용체 작동 활성을 갖는 화합물 및 그 의약 용도
EP3053961B1 (en) 2013-10-02 2018-06-06 Kuraray Co., Ltd. Resin composition, multi-layer sheet, packaging material, and container
WO2018013676A1 (en) 2016-07-14 2018-01-18 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US20200000816A1 (en) 2017-02-08 2020-01-02 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
BR112019019168A2 (pt) 2017-03-16 2020-04-14 Crinetics Pharmaceuticals Inc moduladores de somatostatina e usos dos mesmos
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019157458A1 (en) 2018-02-12 2019-08-15 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TW202024095A (zh) 2018-09-18 2020-07-01 美商克林提克斯醫藥股份有限公司 生長抑制素(somatostatin)調節劑及其用途
BR112022002683A2 (pt) 2019-08-14 2022-07-05 Crinetics Pharmaceuticals Inc Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos

Also Published As

Publication number Publication date
EP4013748A1 (en) 2022-06-22
IL290479A (en) 2022-04-01
JP2022544055A (ja) 2022-10-17
CL2022000354A1 (es) 2022-10-21
BR112022002683A2 (pt) 2022-07-05
CN114585614A (zh) 2022-06-03
ZA202201829B (en) 2023-07-26
EP4013748A4 (en) 2023-08-09
AR119753A1 (es) 2022-01-12
US20220144802A1 (en) 2022-05-12
TW202115008A (zh) 2021-04-16
US11479540B2 (en) 2022-10-25
WO2021030262A1 (en) 2021-02-18
CA3149840A1 (en) 2021-02-18
CO2022002781A2 (es) 2022-06-21
AU2020327950A1 (en) 2022-03-17
KR20220047318A (ko) 2022-04-15
US20210047287A1 (en) 2021-02-18
PE20221402A1 (es) 2022-09-15

Similar Documents

Publication Publication Date Title
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
NZ757081A (en) Somatostatin modulators and uses thereof
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MX2020013085A (es) Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
CR20210615A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021015508A (es) Carbamatos de piridina y su uso como moduladores del receptor glun2b.
JOP20210328A1 (ar) مركبات أميدات بيريدين-بيرازولو المستبدلة واستخدامها باعتبارها معدِّلات لمستقبل الغلوتومات "glun2b"
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2021015511A (es) Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2022000712A (es) Moduladores de nlrp3.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.